A report explored associations between weight fluctuations and cardiovascular outcomes in individuals with type 2 diabetes who were treated with canagliflozin.
All articles by Lauren Evoy Davis, MA
Researchers examined the time to fibrosis progression among patients with and without type 2 diabetes who had NAFLD.
Publish Date
Researchers evaluated differences in the association between obesity and cardiovascular disease.
Publish Date
-
Latest News Your top articles for Monday
For More Personalized News -
Haymarket Medical NetworkTop Picks
- Loading...
Continuing Medical Education (CME/CE) Courses
